Personal information

Breast Cancer, Ductal Carcinoma In Situ, Pathology, Molecular Biology, Overdiagnosis, Overtreatment, Neoadjuvant treatment
Netherlands

Activities

Employment (2)

Leiden University Medical Center: Leiden, NL

2018-07-01 to present | Professor of Breast Pathology (Department of Pathology)
Employment
Source: Self-asserted source
Jelle Wesseling

Netherlands Cancer Institute - Antoni van Leeuwenhoek: Amsterdam, NL

2006-07-01 to present | Principal Investigator & Breast Pathologist (Divisions of Diagnostic Oncology & Molecular Pathology)
Employment
Source: Self-asserted source
Jelle Wesseling

Funding (5)

Prevent Ductal Carcinoma in Situ Invasive Overtreatment Now - PRECISION

2017-05-01 to 2022-04-30 | Grant
Dutch Cancer Society (Amsterdam, NL)
GRANT_NUMBER: 8258
Source: Self-asserted source
Jelle Wesseling via DimensionsWizard

Prevent Ductal Carcinoma in Situ Invasive Overtreatment Now - PRECISION

2017-05-01 to 2022-04-30 | Grant
Cancer Research UK (London, GB)
GRANT_NUMBER:

CRUK-A24043

Source: Self-asserted source
Jelle Wesseling via DimensionsWizard

Management of low grade ductal carcinoma in situ: active surveillance or not? A randomized, non-inferiority phase III trial (LORD studie) (BOOG)

2016-07-01 to 2020-06-30 | Grant
Dutch Cancer Society (Amsterdam, NL)
GRANT_NUMBER: 7711
Source: Self-asserted source
Jelle Wesseling via DimensionsWizard

Secondary prevention of breast cancer: risk stratification for personalized management of screen-detected ductal carcinoma in situ (DCIS)

2015-10-01 to 2019-10-01 | Grant
Dutch Cancer Society (Amsterdam, NL)
GRANT_NUMBER: NKI 2014-7167
Source: Self-asserted source
Jelle Wesseling via DimensionsWizard

MANAGEMENT OF LOW RISK DUCTAL CARCINOMA IN SITU: WATCHFUL WAITING OR NOT? A RANDOMIZED, NON-INFERIORITY TRIAL

2015-02-01 to 2021-02-01 | Grant
Dutch Cancer Society (Amsterdam, NL)
GRANT_NUMBER: NKI 2014-6250
Source: Self-asserted source
Jelle Wesseling via DimensionsWizard

Works (50 of 233)

Items per page:
Page 1 of 5

Watchful waiting for ductal carcinoma in situ: are we ready to step back?

European Radiology
2025-02-06 | Journal article
Contributors: Esther H. Lips; Margot Nieberg; Jelle Wesseling
Source: check_circle
Crossref

Conquering Overtreatment of DCIS: Lessons from PRECISION

Cancer Discovery
2025-01-13 | Journal article
Contributors: Proteeti Bhattacharjee; Esther H. Lips; Elinor J. Sawyer; E. Shelley Hwang; Alastair M. Thompson; Jelle Wesseling; Fariba Behbod; Proteeti Bhattacharjee; Deborah Collyar; Helen Davies et al.
Source: check_circle
Crossref

Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade

British Journal of Cancer
2024-09-21 | Journal article
Contributors: Rebecca L. O’Leary; Lucien E. M. Duijm; Liesbeth J. Boersma; Maurice J. C. van der Sangen; Linda de Munck; Jelle Wesseling; Robert-Jan Schipper; Adri C. Voogd
Source: check_circle
Crossref

Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance

Breast Cancer Research
2024-08-27 | Journal article
Contributors: Mieke R. Van Bockstal; Jelle Wesseling; Ester H. Lips; Marjolein Smidt; Christine Galant; Carolien H. M. van Deurzen
Source: check_circle
Crossref

Clinicopathological and prognostic value of calcification morphology descriptors in ductal carcinoma in situ of the breast: a systematic review and meta-analysis

Insights into Imaging
2023-12-05 | Journal article
Contributors: Merle M. van Leeuwen; Shannon Doyle; Alexandra W. van den Belt–Dusebout; Stevie van der Mierden; Claudette E. Loo; Ritse M. Mann; Jonas Teuwen; Jelle Wesseling
Source: check_circle
Crossref

Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights

British Journal of Cancer
2023-09-07 | Journal article
Contributors: Marte C. Liefaard; Kat S. Moore; Lennart Mulder; Daan van den Broek; Jelle Wesseling; Gabe S. Sonke; Lodewyk F. A. Wessels; Matti Rookus; Esther H. Lips
Source: check_circle
Crossref

Absence of Lipopolysccharide (LPS) expression in Breast Cancer Cells

2023-08-28 | Preprint
Contributors: Noel FCC de Miranda; Vincent THBM Smit; Manon van der Ploeg; Jelle Wesseling; Jacques Neefjes
Source: check_circle
Crossref

Tumour-educated platelets for breast cancer detection: biological and technical insights

British Journal of Cancer
2023-04-12 | Journal article
Contributors: Marte C. Liefaard; Kat S. Moore; Lennart Mulder; Daan van den Broek; Jelle Wesseling; Gabe S. Sonke; Lodewyk F. A. Wessels; Matti Rookus; Esther H. Lips
Source: check_circle
Crossref

Data from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

2023-03-31 | Preprint
Contributors: Tessa G. Steenbruggen; Maartje van Seijen; Liselore M. Janssen; Mette S. van Ramshorst; Erik van Werkhoven; Marie-Jeanne T.D.F. Vrancken Peeters; Jelle Wesseling; Esther H. Lips; Gabe S. Sonke
Source: check_circle
Crossref

Data from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

2023-03-31 | Preprint
Contributors: Tessa G. Steenbruggen; Maartje van Seijen; Liselore M. Janssen; Mette S. van Ramshorst; Erik van Werkhoven; Marie-Jeanne T.D.F. Vrancken Peeters; Jelle Wesseling; Esther H. Lips; Gabe S. Sonke
Source: check_circle
Crossref

Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

2023-03-31 | Preprint
Contributors: Tessa G. Steenbruggen; Maartje van Seijen; Liselore M. Janssen; Mette S. van Ramshorst; Erik van Werkhoven; Marie-Jeanne T.D.F. Vrancken Peeters; Jelle Wesseling; Esther H. Lips; Gabe S. Sonke
Source: check_circle
Crossref

Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

2023-03-31 | Preprint
Contributors: Tessa G. Steenbruggen; Maartje van Seijen; Liselore M. Janssen; Mette S. van Ramshorst; Erik van Werkhoven; Marie-Jeanne T.D.F. Vrancken Peeters; Jelle Wesseling; Esther H. Lips; Gabe S. Sonke
Source: check_circle
Crossref

Supplementary Data from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

2023-03-31 | Preprint
Contributors: Tessa G. Steenbruggen; Maartje van Seijen; Liselore M. Janssen; Mette S. van Ramshorst; Erik van Werkhoven; Marie-Jeanne T.D.F. Vrancken Peeters; Jelle Wesseling; Esther H. Lips; Gabe S. Sonke
Source: check_circle
Crossref

Supplementary Data from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

2023-03-31 | Preprint
Contributors: Tessa G. Steenbruggen; Maartje van Seijen; Liselore M. Janssen; Mette S. van Ramshorst; Erik van Werkhoven; Marie-Jeanne T.D.F. Vrancken Peeters; Jelle Wesseling; Esther H. Lips; Gabe S. Sonke
Source: check_circle
Crossref

Beyond the snapshot: optimizing prognostication and prediction by moving from fixed to functional multidimensional cancer pathology

The Journal of Pathology
2022-07 | Journal article
Contributors: CJH Kramer; MPG Vreeswijk; B Thijssen; T Bosse; J Wesseling
Source: check_circle
Crossref

Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients

The Breast
2021-12 | Journal article
Contributors: Max A.A. Ragusi; Tycho Bismeijer; Bas H.M. van der Velden; Claudette E. Loo; Sander Canisius; Jelle Wesseling; Lodewyk F.A. Wessels; Sjoerd G. Elias; Kenneth G.A. Gilhuijs
Source: check_circle
Crossref

Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists

Cancers
2021-08-06 | Journal article
Contributors: Danalyn Byng; Valesca Retèl; Ellen Engelhardt; Catharina Groothuis-Oudshoorn; Janine van Til; Renée Schmitz; Frederieke van Duijnhoven; Jelle Wesseling; Eveline Bleiker; Wim van Harten et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer

Breast Cancer Research and Treatment
2021-08-04 | Journal article
Contributors: Emma J. Groen; Marieke E. M. van der Noordaa; Michael Schaapveld; Gabe S. Sonke; Ritse M. Mann; Mette S. van Ramshorst; Esther H. Lips; Marie-Jeanne T. F. D. Vrancken Peeters; Frederieke H. van Duijnhoven; Jelle Wesseling
Source: check_circle
Crossref

Personalized early detection and prevention of breast cancer: ENVISION consensus statement

Nature Reviews Clinical Oncology
2020 | Journal article
Source: Self-asserted source
Jelle Wesseling

Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression.

Radiology
2020 | Journal article
Source: Self-asserted source
Jelle Wesseling
grade
Preferred source (of 2)‎

Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03).

Radiother.Oncol.
2020 | Journal article
Source: Self-asserted source
Jelle Wesseling

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review

Breast.
2020 | Journal article
Source: Self-asserted source
Jelle Wesseling

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?

European journal of radiology
2019 | Journal article
Source: Self-asserted source
Jelle Wesseling

Avoiding Overtreatment of Ductal Carcinoma in situ

Trends in Cancer
2019 | Journal article
Source: Self-asserted source
Jelle Wesseling
grade
Preferred source (of 2)‎

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.

The American Journal of Surgical Pathology
2019 | Journal article
Source: Self-asserted source
Jelle Wesseling

MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial

Lancet Oncology
2019 | Journal article
Source: Self-asserted source
Jelle Wesseling

Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses.

Cancer Epidemiology Biomarkers & Prevention
2019 | Journal article
Source: Self-asserted source
Jelle Wesseling
grade
Preferred source (of 2)‎

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study.

Breast Cancer Research and Treatment
2019 | Journal article
Source: Self-asserted source
Jelle Wesseling

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

Clinical Cancer Research
2019-08-15 | Journal article
Contributors: Tessa G. Steenbruggen; Maartje van Seijen; Liselore M. Janssen; Mette S. van Ramshorst; Erik van Werkhoven; Marie-Jeanne T.D.F. Vrancken Peeters; Jelle Wesseling; Esther H. Lips; Gabe S. Sonke
Source: check_circle
Crossref

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

European Journal of Cancer
2018 | Journal article
Source: Self-asserted source
Jelle Wesseling

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

European Journal of Cancer
2018 | Journal article
Source: Self-asserted source
Jelle Wesseling

Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012

European Journal of Cancer
2018 | Journal article
Source: Self-asserted source
Jelle Wesseling

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ.

Annals of Surgery
2018 | Journal article
Source: Self-asserted source
Jelle Wesseling

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.

Clin Cancer Res.
2018 | Journal article
Source: Self-asserted source
Jelle Wesseling

Enrichment of high-grade tumors in breast cancer gene expression studies.

Breast Cancer Research and Treatment
2018 | Journal article
Source: Self-asserted source
Jelle Wesseling

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome

Molecular Oncology
2018 | Journal article
Source: Self-asserted source
Jelle Wesseling

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.

BMC Cancer
2018 | Journal article
Source: Self-asserted source
Jelle Wesseling

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Lancet Oncology
2018 | Journal article
Source: Self-asserted source
Jelle Wesseling

The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.

BMC Cancer
2018 | Journal article
Source: Self-asserted source
Jelle Wesseling

Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study

Genes
2018-05-17 | Journal article
Contributors: Julia E.C. Van Steenhoven; Anne Kuijer; Paul J. Van Diest; Joost M. Van Gorp; Marieke Straver; Sjoerd G. Elias; Jelle Wesseling; Emiel Rutgers; Johanna N.H. Timmer-Bonte; Peter Nieboer et al.
Source: check_circle
Crossref

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.

Cancer imaging : the official publication of the International Cancer Imaging Society
2017 | Journal article
Source: Self-asserted source
Jelle Wesseling

Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women

Journal of the National Cancer Institute
2017 | Journal article
Source: Self-asserted source
Jelle Wesseling

Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Breast Cancer Research and Treatment
2017 | Journal article
Source: Self-asserted source
Jelle Wesseling

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)

The Breast
2017 | Journal article
Source: Self-asserted source
Jelle Wesseling

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

Nature Genetics
2017 | Journal article
Source: Self-asserted source
Jelle Wesseling

Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review

Critical Reviews in Oncology/Hematology
2017 | Journal article
Source: Self-asserted source
Jelle Wesseling

Impact of 70-gene signature use on adjuvant chemotherapy decisions in patients with estrogen receptor–positive early breast cancer: Results of a prospective cohort study

Journal of Clinical Oncology
2017 | Journal article
Source: Self-asserted source
Jelle Wesseling

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

Nature Genetics
2017 | Journal article
Source: Self-asserted source
Jelle Wesseling

Long-Term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: Protocol for the PARADIGM initiative cohort study

BMJ open
2017 | Journal article
Source: Self-asserted source
Jelle Wesseling

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes

PLoS ONE
2017 | Journal article
Source: Self-asserted source
Jelle Wesseling
Items per page:
Page 1 of 5

Peer review (9 reviews for 6 publications/grants)

Review activity for Breast cancer research and treatment. (2)
Review activity for European journal of cancer. (2)
Review activity for Nature communications (1)
Review activity for Nature reviews. (1)
Review activity for NPJ breast cancer. (2)
Review activity for Virchows Archiv (1)